Angiotech Pharmaceuticals launches the Tan EndoGlide Endothelium Insertion System in the U.S.

NewsGuard 100/100 Score

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Tan EndoGlide(TM) Endothelium Insertion System in the United States. Angiotech holds exclusive U.S. distribution rights to market and distribute the Tan EndoGlide Endothelium Insertion System, which it obtained in a supply agreement with privately held Network Medical Products, Ltd. Angiotech will launch the product during the American Academy of Ophthalmology meeting, to be held in San Francisco, CA on October 24-27, 2009.

"As less invasive cornea transplant techniques continue to evolve, new devices are needed to safely deliver donor tissue. The Tan EndoGlide is one of the first new devices on the market designed to help surgeons handle and insert endothelial cell tissue with minimal cell loss," said Steve Bryant, Senior Vice President, Sales and Marketing for Angiotech. "We are excited to announce that the Tan EndoGlide Endothelium Insertion System is now available throughout the U.S. through our Ophthalmic Distributor Specialties Sales Team."

The Tan EndoGlide is a device used to facilitate insertion of a donor endothelium during Endothelial Keratoplasty. The device is used by Ophthalmologists adapting to newer techniques to replace diseased corneal endothelium. The Tan EndoGlide is specifically designed for use in Descemet's Stripping Endothelial Keratoplasty (DSEK) and Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) surgical procedures.


Angiotech Pharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics